Phase 1 / Phase 2 trials
Phase 1 / Phase 2 trials
Explore registered studies and their research locations.4,324 results · Page 1 of 173
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GST101 in Participants With RAS-Mutant Advanced Solid Tumors | RAS-mutant Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07868172 | |
| A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07798609 | |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | Blood Protein Disorders, DNA Virus Infections, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, agammaglobulinemia, common wart, hematologic disorder, human papilloma virus infection, immune system disorder, immunodeficiency disease, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome, skin disorder, skin disorder caused by infection, viral infectious disease | Enrolling by invitation | Phase 1 / Phase 2 | 2026-10-09 | NCT07775313 | |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07735533 | |
| A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors | Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07698587 | |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nose Neoplasms, Oral Squamous Cell Carcinoma, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoid cystic carcinoma, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, hypopharynx cancer, laryngeal carcinoma, laryngeal disorder, laryngeal neoplasm, male reproductive organ cancer, male reproductive system disorder, mouth disorder, nasal disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, oropharynx squamous cell carcinoma, otorhinolaryngologic disease, paranasal sinus disorder, paranasal sinus neoplasm, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, squamous cell carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07667400 | |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, scleroderma, skin disorder, systemic sclerosis | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07641634 | |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07612787 | |
| Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07587515 | |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) | post-transplant lymphoproliferative disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07573436 | |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07529717 | |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07468071 | |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07288359 | |
| A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07266428 | |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07227597 | |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07226986 | |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Progressive Metastatic Castrate Resistant Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07206056 | |
| A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) | Influenza A | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07128615 | |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07128381 | |
| A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07126665 | |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, gastric neoplasm, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07070232 | |
| A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07060989 | |
| 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06991738 | |
| A Study of MHB046C Injection in Patients With Advanced Solid Tumors | Advanced Solid Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06985355 | |
| CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia | Bacterial Infections and Mycoses, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pneumocystis infectious disease, Pneumocystis jirovecii Infection, Respiration Disorders, Respiratory Aspiration, fungal infectious disease, fungal lung infectious disease, interstitial lung disease, lung disorder, pneumocystosis, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06892951 |